|
| Variable | Value |
|
| Mean basal hemoglobin (g/dl) | 8.8 ± 1.9 |
| Mean hemoglobin during EPO treatment (g/dl) (%) | |
| (i) Less than 11 | 178 (77.4) |
| (ii) Between 11 and 12 | 29 (12.6) |
| (iii) More than 12 | 23 (10) |
| Mean hematocrit during EPO treatment (%) | 28.9 ± 5.2 |
| Mean serum potassium during EPO treatment (mEq/L) | 4.3 ± 0.5 |
| Mean systolic blood pressure (mm Hg) | 119.5 ± 15.4 |
| Mean diastolic blood pressure (mm Hg) | 73.50 ± 7.6 |
| Glomerular filtration rate (ml/min/1.73 m2) | |
| (i) Less than 60 | 101 (78.3) |
| (ii) Equal or more than 60 | 28 (21.7) |
| Transferrin saturation, n (%) | 78 (18.5) |
| Serum ferritin level (ng/ml) | 5.517 |
| Prescribing iron supplements, n (%) | |
| (i) Injectable form | 34 (14.8) |
| (ii) Oral form | 13 (5.6) |
| Prescribing folic acid tablets, n (%) | 137 (59.6) |
| Prescribing vitamin B12 ampoules, n (%) | 46 (20) |
| EPO brand, n (%) | |
| (i) PDpoietin® (EPO alpha) | 121 (52.6) |
| (ii) Cinnapoietin® (EPO beta) | 109 (47.4) |
| Indication for prescription, n (%) | |
| (i) Anemia due to chronic kidney disease | 129 (56.1) |
| (ii) Anemia due to chemotherapy | 13 (5.7) |
| (iii) Anemia due to chronic disease | 88 (38.3) |
| Number of EPO injections per week, n (%) | |
| (i) Once a week | 21 (9.1) |
| (ii) Twice a week | 52 (22.6) |
| (iii) Three times a week | 157 (68.3) |
| Response to EPO, n (%) | |
| (i) Adequate response | 124 (53.9) |
| (ii) Over response | 15 (6.5) |
| (iii) Under response | 91 (39.6) |
| Dose modification of EPO, n (%) | |
| (i) No dose change | 126 (54.8) |
| (ii) Dose reduction | 15 (6.5) |
| (iii) Dose increase | 89 (38.7) |
|
